Journal
SEMINARS IN CANCER BIOLOGY
Volume 86, Issue -, Pages 645-663Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2022.04.004
Keywords
Cancer; Nano -therapeutics; Anti-inflammatory nanomedicines; Patents; Clinical translation
Categories
Ask authors/readers for more resources
The study emphasizes the importance and challenges of nanotechnology in cancer treatment, highlighting the need to overcome issues in developing anti-inflammatory nanomedicines.
Evident role of inflammation in cancer development and progression prompted the application of antiinflammatory medications as a therapeutic strategy. The major bottleneck for the anti-inflammatory drugs is targeted delivery to the cancerous cell. Nanotechnology has provided safe and effective way for targeted cancer therapy. However, the complex and heterogeneous traits of cancer, incomplete information on fate and behavior of nanomedicines in human body, and lack of large-scale commercial production have slowed down the pace of nanomedicines development. To shift the paradigm from conventional cancer therapeutics to anti-inflammatory nano-therapeutics, thorough understanding of the strategies, progress, success, challenges and future perspectives are needed. The present review highlights all these aspects in addition to innovations patented on them. In fact, patent plays a vital role in protection of innovations, and further translation of lab-scale outcomes into bedside medications. Thus, the review introspects and recognizes the glitches in successful clinical translation of anti-inflammatory nanomedicines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available